We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Prestige Consumer Healthcare Inc. (NYSE:PBH) is among the most undervalued stocks to invest in.
TheFly reported on May 15 that Canaccord Genuity cut its price target on PBH from $86 down to $72 while keeping a Buy rating in place. The adjustment came after a weaker Q4 result, driven largely by softness in the eye care segment along with additional pressure linked to the Iran conflict, prompting the firm to revise its model.
Separately, on May 13, Prestige Consumer Healthcare Inc. (NYSE:PBH) disclosed a definitive agreement to acquire LaCorium Health in an all-cash deal valued at about $150 million. The transaction is still subject to standard closing conditions and is expected to be completed during the second quarter of fiscal 2027. Based on financial data provided, LaCorium recorded roughly $40 million in revenue over the trailing twelve months ending February 28.
The business is projected to contribute around $12 million in EBITDA after the anticipated benefits from integration synergies are realized. In addition, LaCorium is expected to deliver double-digit net sales growth during calendar year 2026, indicating continued expansion before full integration. The acquisition is positioned as a strategic addition that will be incorporated into Prestige’s broader operations once finalized, strengthening its portfolio and supporting longer-term growth and profitability objectives within its consumer healthcare segment.
Prestige Consumer Healthcare Inc. (NYSE:PBH) is a leading provider of over-the-counter health, wellness, and personal care products. Headquartered in Tarrytown, New York, it manages a portfolio of well-known consumer health brands.
TheFly reported on May 15 that Canaccord Genuity cut its price target on PBH from $86 down to $72 while keeping a Buy rating in place. The adjustment came after a weaker Q4 result, driven largely by softness in the eye care segment along with additional pressure linked to the Iran conflict, prompting the firm to revise its model.
Separately, on May 13, Prestige Consumer Healthcare Inc. (NYSE:PBH) disclosed a definitive agreement to acquire LaCorium Health in an all-cash deal valued at about $150 million. The transaction is still subject to standard closing conditions and is expected to be completed during the second quarter of fiscal 2027. Based on financial data provided, LaCorium recorded roughly $40 million in revenue over the trailing twelve months ending February 28.
The business is projected to contribute around $12 million in EBITDA after the anticipated benefits from integration synergies are realized. In addition, LaCorium is expected to deliver double-digit net sales growth during calendar year 2026, indicating continued expansion before full integration. The acquisition is positioned as a strategic addition that will be incorporated into Prestige’s broader operations once finalized, strengthening its portfolio and supporting longer-term growth and profitability objectives within its consumer healthcare segment.
Prestige Consumer Healthcare Inc. (NYSE:PBH) is a leading provider of over-the-counter health, wellness, and personal care products. Headquartered in Tarrytown, New York, it manages a portfolio of well-known consumer health brands.
16 hours ago
